Jazz Pharmaceuticals: Pay

Jazz Pharmaceuticals paid its 5 named executives $57.9M in total in FY2025 (Dec). CEO Renee D. Gala was paid $19.2M of that.

Pay$100 in the stock at the end of FY22 → $107
CEO pay is from each proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Pay of each named executive

Renee D. GalaPresident, CEO and Director
FY2025 (Dec)
FY2024 (Dec)Not disclosed
FY2023 (Dec)Not disclosed
3 years
Bruce C. CozaddChairperson and former CEO
FY2025 (Dec)
FY2024 (Dec)
FY2023 (Dec)
FY2022 (Dec)Not disclosed
FY2021 (Dec)Not disclosed
5 years
Philip L. JohnsonExecutive Vice President and CFO
FY2025 (Dec)
FY2024 (Dec)
2 years
Neena M. PatilExecutive Vice President and Chief Legal Officer
FY2025 (Dec)
FY2024 (Dec)Not disclosed
FY2023 (Dec)
3 years
Samantha PearceExecutive Vice President, Chief Commercial Officer
FY2025 (Dec)
FY2024 (Dec)
2 years
Robert Iannone, M.D., M.S.C.EExecutive Vice President, Global Head of R&D
FY2024 (Dec)
FY2023 (Dec)
FY2022 (Dec)Not disclosed
FY2021 (Dec)Not disclosed
4 years

CEO pay against the pay peers

In FY2025 (Dec), the median CEO pay of the 10 peers with pay on file was $19.0M. CEO pay of Jazz Pharmaceuticals for that year is not on file.

  1. 1Exelixis
  2. 2Incyte
  3. 3Gilead Sciences
  4. 4Biomarin Pharmaceutical
  5. 5Moderna
  6. 6United Therapeutics
  7. 7Alnylam Pharmaceuticals
  8. 8Alkermes plc.
  9. 9Regeneron Pharmaceuticals
  10. 10Neurocrine Biosciences
  11. 11Jazz PharmaceuticalsNot disclosed
  12. 12BiogenNot disclosed
  13. 13Organon & Co.Not disclosed
  14. 14Vertex Pharmaceuticals IncorporatedNot disclosed

Pay of each named executive comes from the Summary Compensation Table of each proxy statement. Realized pay adds the value of options used and stock that vested. CEO pay of each peer comes from its own Pay versus Performance table.